Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer

2016 ◽  
Vol 41 (6) ◽  
pp. 478-480 ◽  
Author(s):  
Carl Diedrich Schlenkhoff ◽  
Florian Gaertner ◽  
Markus Essler ◽  
Matthias Schmidt ◽  
Hojjat Ahmadzadehfar
Keyword(s):  
Prostate Cancer ◽  
Bone Marrow ◽  
Metastatic Prostate Cancer ◽  
Positive Influence ◽  
Bone Marrow Depression

scholarly journals Metastatic prostate cancer with bone marrow infiltration mimicking multiple myeloma

2017 ◽  
Vol 6 (2) ◽  
pp. 269-273 ◽  
Author(s):  
Pankaj Mathur ◽  
Daisy Alapat ◽  
Manoj Kumar ◽  
Sharmilan Thanendrarajan
Keyword(s):  
Prostate Cancer ◽  
Multiple Myeloma ◽  
Bone Marrow ◽  
Metastatic Prostate Cancer ◽  
Bone Marrow Infiltration

scholarly journals Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Jeremy J. McGuire ◽  
Jeremy S. Frieling ◽  
Chen Hao Lo ◽  
Tao Li ◽  
Ayaz Muhammad ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Marrow ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cancer Cells ◽  
Metastatic Prostate Cancer ◽  
Prostate Cancer Cell ◽  
Prostate Cancer Cells ◽  
Interleukin 28 ◽  
Selection Of

AbstractBone metastatic prostate cancer (PCa) promotes mesenchymal stem cell (MSC) recruitment and their differentiation into osteoblasts. However, the effects of bone-marrow derived MSCs on PCa cells are less explored. Here, we report MSC-derived interleukin-28 (IL-28) triggers prostate cancer cell apoptosis via IL-28 receptor alpha (IL-28Rα)-STAT1 signaling. However, chronic exposure to MSCs drives the selection of prostate cancer cells that are resistant to IL-28-induced apoptosis and therapeutics such as docetaxel. Further, MSC-selected/IL-28-resistant prostate cancer cells grow at accelerated rates in bone. Acquired resistance to apoptosis is PCa cell intrinsic, and is associated with a shift in IL-28Rα signaling via STAT1 to STAT3. Notably, STAT3 ablation or inhibition impairs MSC-selected prostate cancer cell growth and survival. Thus, bone marrow MSCs drive the emergence of therapy-resistant bone metastatic prostate cancer yet this can be disabled by targeting STAT3.

scholarly journals Bone Marrow Metastatic Prostate Cancer Representing Itself With Deep Anemia

2019 ◽  
Vol 02 (03) ◽  
Author(s):  
Aktas Yasin ◽  
Karam k Kaan ◽  
Mehmet Salih Boga ◽  
Yldrm Senay ◽  
Islamoglu Ekrem ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Marrow ◽  
Metastatic Prostate Cancer

Abstract IA23: Impact of metastatic prostate cancer on human bone marrow

2020 ◽  
Author(s):  
Ninib Baryawno ◽  
Youmna Kfoury ◽  
Nicolas Severe ◽  
Shenglin Mei ◽  
Karin Gustafsson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Marrow ◽  
Metastatic Prostate Cancer ◽  
Human Bone ◽  
Human Bone Marrow
Sign in / Sign up

Export Citation Format

Share Document